These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 30709064)

  • 1. Colistin Use in Patients with Extreme Renal Function: From Dialysis to Augmented Clearance.
    Aitullina A; Krūmiņa A; Svirskis Š; Purviņa S
    Medicina (Kaunas); 2019 Jan; 55(2):. PubMed ID: 30709064
    [No Abstract]   [Full Text] [Related]  

  • 2. Ten-year Single Center Experience With Colistin Therapy in NICU.
    Kaya TB; Sürmeli Onay Ö; Aydemir Ö; Tekin AN
    Pediatr Infect Dis J; 2024 Feb; 43(2):165-169. PubMed ID: 37820257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nephrotoxicity caused by colistin use in ICU: a single centre experience.
    Kilic I; Ayar Y; Ceylan İ; Kaya PK; Caliskan G
    BMC Nephrol; 2023 Oct; 24(1):302. PubMed ID: 37833622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors and prognosis for the development of acute kidney injury in patients using colistin in the intensive care unit: A retrospective cohort study.
    Deniz M; Alişik M
    Medicine (Baltimore); 2024 Jan; 103(2):e36913. PubMed ID: 38215139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Machine learning algorithms to predict colistin-induced nephrotoxicity from electronic health records in patients with multidrug-resistant Gram-negative infection.
    Chiu LW; Ku YE; Chan FY; Lie WN; Chao HJ; Wang SY; Shen WC; Chen HY
    Int J Antimicrob Agents; 2024 Jul; 64(1):107175. PubMed ID: 38642812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attributable Risk and Time Course of Colistin-Associated Acute Kidney Injury.
    Miano TA; Lautenbach E; Wilson FP; Guo W; Borovskiy Y; Hennessy S
    Clin J Am Soc Nephrol; 2018 Apr; 13(4):542-550. PubMed ID: 29545383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical Analysis of Colistin Sulfate in the Treatment of Hematonosis Infected by Multidrug-Resistant Gram-Negative Bacteria].
    Wu YB; Jiang SS; Wu YX; Li DY; Li Q; Wang X; Liu B; Bao HY; Hu XH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1878-1884. PubMed ID: 38071076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parenteral polymyxins: assessing efficacy and safety in critically ill patients with renal dysfunction.
    Sekhri K; Nandha R; Mandal A; Bhasin D; Singh H
    Indian J Pharmacol; 2013; 45(6):608-11. PubMed ID: 24347770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Augmented Renal Clearance in the Hematology and Oncology Populations: A Scoping Review for Pharmacists.
    Nelson NR; Mendoza C; Rhoney DH
    J Pharm Pract; 2023 Dec; 36(6):1485-1497. PubMed ID: 35972988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Augmented renal clearance: a retrospective, cohort study of urinary creatinine clearance in critically ill patients in the United Kingdom.
    Johnston BW; Perry D; Habgood M; Joshi M; Krige A
    J Int Med Res; 2021 May; 49(5):3000605211015573. PubMed ID: 34038207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Personalized application of antimicrobial drugs in pediatric patients with augmented renal clearance: a review of literature.
    Xu WX; Qu Q; Teng XQ; Zhuang HH; Liu SF; Wang Y; Qu J
    Eur J Pediatr; 2024 Jan; 183(1):51-60. PubMed ID: 37861791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic predisposition and high exposure to colistin in the early treatment period as independent risk factors for colistin-induced nephrotoxicity.
    Mathew SK; Chapla A; Venkatesan P; Eriyat V; Aruldhas BW; Prabha R; Neely MN; Rao SV; Kandasamy S; Mathew BS
    Clin Transl Sci; 2024 Mar; 17(3):e13764. PubMed ID: 38476095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comment on 'Acute kidney injury associated with colistin sulfate vs. polymyxin B sulfate therapy: A real-world, retrospective cohort study'.
    Zhang CJ; Ma XD; Shen M; Zhou XC; Qiu G
    Int J Antimicrob Agents; 2024 Jul; 64(1):107179. PubMed ID: 38677527
    [No Abstract]   [Full Text] [Related]  

  • 14. In reply to the Letter to Editor regarding "Acute kidney injury associated with colistin sulfate vs. polymyxin B sulfate therapy: A real-world, retrospective cohort study".
    Zhang Y; Ye Z; Jiang S
    Int J Antimicrob Agents; 2024 Jul; 64(1):107178. PubMed ID: 38677528
    [No Abstract]   [Full Text] [Related]  

  • 15. Dextrin conjugation to colistin inhibits its toxicity, cellular uptake and acute kidney injury
    Varache M; Rizzo S; Sayers EJ; Newbury L; Mason A; Liao CT; Chiron E; Bourdiec N; Jones A; Fraser DJ; Taylor PR; Jones AT; Thomas DW; Ferguson EL
    RSC Pharm; 2024 Apr; 1(1):68-79. PubMed ID: 38646595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individualized antibiotic dosage regimens for patients with augmented renal clearance.
    Shi AX; Qu Q; Zhuang HH; Teng XQ; Xu WX; Liu YP; Xiao YW; Qu J
    Front Pharmacol; 2023; 14():1137975. PubMed ID: 37564179
    [No Abstract]   [Full Text] [Related]  

  • 17. Prevalence of polymyxin-induced nephrotoxicity and its predictors in critically ill adult patients: A meta-analysis.
    Wang JL; Xiang BX; Song XL; Que RM; Zuo XC; Xie YL
    World J Clin Cases; 2022 Nov; 10(31):11466-11485. PubMed ID: 36387815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are Antibiotics Appropriately Dosed in Critically Ill Patients with Augmented Renal Clearance? A Narrative Review.
    Sistanizad M; Hassanpour R; Pourheidar E
    Int J Clin Pract; 2022; 2022():1867674. PubMed ID: 35685541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose Optimization of Colistin: A Systematic Review.
    Haseeb A; Faidah HS; Alghamdi S; Alotaibi AF; Elrggal ME; Mahrous AJ; Almarzoky Abuhussain SS; Obaid NA; Algethamy M; AlQarni A; Khogeer AA; Saleem Z; Sheikh A
    Antibiotics (Basel); 2021 Nov; 10(12):. PubMed ID: 34943666
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.